WALTHAM -
The webcast for this conference may be accessed at the 'Events & Presentations' page within the Investors section of the Spyre website at ir.spyre.com. A replay of the webcast will be available for 90 days following the conference.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23.
Contact:
Email: Eric.mcintyre@spyre.com
Email: Peg.rusconi@vergescientific.com
(C) 2023 Electronic News Publishing, source